ARLZ - Aralez Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.0345
-0.0084 (-19.58%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.0429
Open0.0400
Bid0.0000 x 28000
Ask0.0000 x 1100
Day's Range0.0255 - 0.0406
52 Week Range0.0255 - 2.2500
Volume6,636,725
Avg. Volume4,175,335
Market Cap17.931M
Beta (3Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)-1.7610
Earnings DateAug 27, 2018 - Sep 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2013-12-31
1y Target Est2.00
Trade prices are not sourced from all markets
  • The Wall Street Journal28 days ago

    [$$] Aralez in Stalking Horse Deals With Nuvo, Deerfield

    Aralez Pharmaceuticals Inc. on Wednesday said it signed “stalking horse” agreements to sell its main operating businesses in a pair of deals valued at $240 million. Aralez said health-care investment firm Deerfield Management Co., its secured lender, agreed to buy its Toprol-XL franchise in a deal valued at $130 million. Deerfield also provided a commitment to finance the Nuvo transaction.

  • The Wall Street Journal2 months ago

    [$$] Drug Company Aralez Files for Bankruptcy, Plans to Sell Most Assets

    Inc., struggling against competition from generic drugmakers, filed for bankruptcy in New York on Friday with plans to sell its main operating businesses. Separately, it plans to sell its blood-pressure-treating Toprol-XL franchise to its secured lender, funds managed by Deerfield Management Co., in a deal valued at $140 million. The specialty pharmaceuticals company has more than $200 million in term loans and $75.5 million in convertible notes outstanding from funds managed by Deerfield.

  • Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets
    PR Newswire2 months ago

    Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets

    MISSISSAUGA, Ontario, Aug. 10, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO) ("Aralez" or the "Company") announced today that it intends to enter into purchase agreements with two separate stalking-horse purchasers to sell its main operating businesses:  an agreement to sell its VIMOVO® royalties and Canadian operations to Nuvo Pharmaceuticals Inc. ("Nuvo") in a transaction valued at U.S.$110 million and an agreement to sell its TOPROL-XL® Franchise to its secured lender, certain funds managed by Deerfield Management Company, L.P., in a transaction valued at U.S.$140 million. The Company is also engaged in ongoing efforts to sell the assets not being sold in either of the proposed transactions and intends to wind down its operations following the consummation of the sales.

  • Aralez Enters Into Amendment To Second Amended And Restated Facility Agreement
    PR Newswire4 months ago

    Aralez Enters Into Amendment To Second Amended And Restated Facility Agreement

    MISSISSAUGA, Ontario, June 29, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO) ("Aralez" or the "Company") today announced that, in connection with its review of strategic alternatives, it entered into an Amendment (the "Amendment") to that certain Second Amended and Restated Facility Agreement, dated as of December 7, 2015, as amended on October 3, 2016 (the "Facility Agreement"), by and between the Company and Deerfield Partners, L.P. ("Deerfield") and certain affiliates of each party. Pursuant to the terms of the Amendment, interest due and payable on July 1, 2018 with respect to the loans under the Facility Agreement will be paid in kind, added to the outstanding principal amount of such loans and bear interest at the applicable interest rate of such loans.  The amount of interest paid in kind and the interest thereon is due and payable without premium or penalty on August 15, 2018 or such earlier date as loans maybe become due and payable.

  • Aralez Announces Voting Results From 2018 Annual Meeting Of Shareholders
    PR Newswire4 months ago

    Aralez Announces Voting Results From 2018 Annual Meeting Of Shareholders

    MISSISSAUGA, Ontario , June 29, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced the results of the matters voted ...

  • ACCESSWIRE4 months ago

    Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space

    LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on ANTH sign up now at www.wallstequities.com/registration. The nature of the operations of firms in the Biotech industry makes equities in this space more suited to aggressive, risk-tolerant investors.

  • Interested In Aralez Pharmaceuticals Inc (TSE:ARZ)? Here’s How It Performed Recently
    Simply Wall St.5 months ago

    Interested In Aralez Pharmaceuticals Inc (TSE:ARZ)? Here’s How It Performed Recently

    Investors with a long-term horizong may find it valuable to assess Aralez Pharmaceuticals Inc’s (TSX:ARZ) earnings trend over time and against its industry benchmark as opposed to simply looking atRead More...

  • ACCESSWIRE5 months ago

    Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks

    Stock Research Monitor: AMPE, ANTH, and ARLZ LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . In today's pre-market ...

  • Is There An Opportunity With Aralez Pharmaceuticals Inc’s (TSE:ARZ) 39% Undervaluation?
    Simply Wall St.5 months ago

    Is There An Opportunity With Aralez Pharmaceuticals Inc’s (TSE:ARZ) 39% Undervaluation?

    Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Aralez Pharmaceuticals Inc (TSX:ARZ) as an investment opportunity. If youRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ARLZ earnings conference call or presentation 8-May-18 12:00pm GMT

    Q1 2018 Aralez Pharmaceuticals Inc Earnings Call

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Amedica Corporation and Aralez Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 9, 2018 / Aralez Pharmaceutical shares sunk on Tuesday after reporting first quarter results, despite a third consecutive quarter of positive adjusted EBITDA. Shares of Amedica had a better day yesterday exploding to a close of over 180% after providing Wall Street with some updates on its clinical study activities. The innovative biomaterial company saw its shares explode after providing an update on its clinical study activities including a Single Center Retrospective Comparative Study and a Multi-Center Retrospective Study.

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 8) CONMED Corporation (NASDAQ: CNMD ) Enanta Pharmaceuticals Inc ...

  • Associated Press5 months ago

    Aralez Pharmaceuticals: 1Q Earnings Snapshot

    The Milton, Ontario-based company said it had a loss of 29 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • Aralez Announces First Quarter 2018 Financial Results
    PR Newswire5 months ago

    Aralez Announces First Quarter 2018 Financial Results

    -1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017- MISSISSAUGA, Ontario , May 8, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez ...

  • Aralez Announces New Strategic Direction
    PR Newswire5 months ago

    Aralez Announces New Strategic Direction

    MISSISSAUGA, Ontario, May 8, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO) ("Aralez" or the "Company") today announced that, based on its continuing exploration and evaluation of numerous opportunities to streamline the business, reduce costs, and improve its capital structure and liquidity, it has determined that a new strategic direction is in the best interests of the Company and its stakeholders. This strategic direction will involve (i) a focus on the Company's strong Canadian business, supported by Toprol-XL and its authorized generic (the "Toprol-XL Franchise") as well as Vimovo royalties, and (ii) the discontinuation of the remaining U.S. commercial business.

  • PR Newswire6 months ago

    Aralez To Announce First Quarter 2018 Results On May 8, 2018

    -Executive Management to Host Conference Call on May 8, 2018 at 8:00 a.m. ET - MISSISSAUGA, Ontario , April 27, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced ...

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of ARLZ earnings conference call or presentation 13-Mar-18 12:30pm GMT

    Q4 2017 Aralez Pharmaceuticals Inc Earnings Call

  • Will Aralez Pharmaceuticals Inc’s (TSE:ARZ) Earnings Grow In The Next Couple Of Years?
    Simply Wall St.7 months ago

    Will Aralez Pharmaceuticals Inc’s (TSE:ARZ) Earnings Grow In The Next Couple Of Years?

    The latest earnings update Aralez Pharmaceuticals Inc’s (TSX:ARZ) released in December 2017 suggested company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...

  • Zacks Small Cap Research7 months ago

    ARLZ: Aralez Set for Strong Revenue Growth in 2018

    Aralez (ARLZ) launched Zontivity® in June 2017 and is now promoting the drug with the company’s 75 person sales force to approximately 12,000 cardiologists, primary care physicians, and vascular surgeons. During the fourth quarter of 2017, Aralez saw a 22% increase in new prescriptions compared to the third quarter of 2017 along with a 32% increase in total prescriptions and a 39% increase in retail prescription equivalents (RPEs). The company uses the RPE metric, which is defined as the total pill count divided by 30, to better reflect the fact that many Zontivity® prescriptions are for more than a 30-day supply.

  • Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
    CNW Group7 months ago

    Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results

    Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results

  • Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
    PR Newswire7 months ago

    Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results

    -4Q 2017 Net Revenues Increased to $28.0 Million Versus $20.0 Million in the 4Q 2016- -Full-Year Net Revenues Increased to $105.9 Million Versus $54.3 Million in Full-Year 2016- -Provides 2018 Full-Year ...

  • ACCESSWIRE7 months ago

    Aralez Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Aralez Pharmaceuticals Inc. (NASDAQ: ARZ ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at 8:30 AM Eastern ...

  • Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
    CNW Group7 months ago

    Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018

    Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018